Clinical trials: Esophagus Cancer, Stage I
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, carboplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238147
- Testing
- capecitabine, carboplatin, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura.
- Conditions
- Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer
- Trial name
- PITHAC (NCT06281860)
- Testing
- Cisplatine Teva®
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Dr Jean Yannis PERENTES
Oesophagus Cancer, Elderly Patients
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
Management of elderly patient with cancer is a therapeutic challenge and a public health problem. The mean age of esophageal cancer is 64.5 years and 72.1 years in men and women respectively.
- Trial name
- OSAGE (NCT02735057)
- Testing
- Carboplatin
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the…
- Trial name
- NCT07700420
- Testing
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Esophagogastric Cancer, Moderate to Severe Dysphagia
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.
- Trial name
- NCT03133650
- Testing
- WST 11-mediated VTP therapy
- Where
- 3 sites in United States, Israel
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the…
- Conditions
- Esophageal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00537121
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Brain and Central Nervous System Tumors
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer
- Trial name
- NCT00313599
- Testing
- lapatinib, paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or
Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy
Step 1: Inclusion of eligible patients to carry out a translational search for prognostic and predictive markers of Complete Clinical Response and Pathologic Complete Response (using blood samples and diagnostic biopsies) and to…
- Conditions
- Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or, Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II), Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0
- Trial name
- Esostrate (NCT02551458)
- Testing
- Systematic surgery, Surveillance and rescue surgery in cases of resectable loco-regional recurrence
- Where
- 18 sites in France
- Volunteers
- 188 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
This randomized pilot phase II trial studies how well molecular phenotyping works in predicting response in patients with stage IB-III esophageal cancer who are receiving carboplatin and paclitaxel or oxaliplatin, leucovorin…
- Conditions
- Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma
- Trial name
- NCT02392377
- Testing
- Paclitaxel, Carboplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Mesothelin Positive, Mesothelin-Expressing Tumors
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified)…
- Conditions
- Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas
- Trial name
- NCT06623396
- Testing
- M28z1XXPD1DNR CAR
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Solid Tumour, Gastroesophageal Cancer
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
This study is a Phase I/II trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors. In Phase I the Maximum Tolerated Dose (MTD) will be determined; in Phase II patients with first-line metastatic…
- Trial name
- NCT01611857
- Testing
- Tivantinib, FOLFOX
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- SCRI Development Innovations, LLC
Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
This phase IB/II trial studies the side effects of taladegib, paclitaxel, carboplatin, and external beam radiation therapy and to see how well they work in treating patients with esophageal or gastroesophageal junction cancer…
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7
- Trial name
- NCT02530437
- Testing
- Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma, Adenocarcinoma Of Esophagus
Proton Beam Therapy to Treat Esophageal Cancer
Assess progression-free survival and overall survival of proton beam therapy (PBT) for patients with resectable vs. unresectable esophageal cancer, and to assess patient-reported outcomes of PBT for esophageal cancer at 6 months…
- Trial name
- NCT02023541
- Testing
- Proton beam therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01243398
- Testing
- quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Gastrointestinal Diseases
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
Phase I Objectives Primary: 1. The primary objective of this study is to determine the maximum tolerated dose (MTD) of Docetaxel combined with 5-Fluorouracil and Oxaliplatin (D-FOX) in patients with untreated, locally…
- Trial name
- NCT00526110
- Testing
- 5-Fluorouracil, Docetaxel, Oxaliplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Esophageal Cancer
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544362
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 13 sites in France
- Volunteers
- 33 people
- Sponsor
- Federation Francophone de Cancerologie Digestive